Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
15 janv. 2025 08h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics announces select preliminary fourth quarter and full year 2024 financial results and introduces full year 2025 financial guidance.
Nutrigenomics Industry Sees $15.7 Billion Opportunity by 2034: Obesity Applications Dominate Revenues, Cancer Research Applications to Grow at the Highest CAGR
14 janv. 2025 06h16 HE
|
Research and Markets
Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Nutrigenomics Market by Product, Application, Technique, End-User, and Region" report has been added to ResearchAndMarkets.com's offering. This...
Wellness Genomics Market Forecast Report 2024-2032: Lucrative Opportunities with Expansion into Emerging Markets, Partnerships, Digital Health Platforms Integration, and Preventive Health Programs
14 janv. 2025 04h01 HE
|
Research and Markets
Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Wellness Genomics Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global wellness genomics market...
Baylor Genetics to Integrate with Epic Aura to Enhance Efficiency and Deliver Genetic Testing Results to Hospitals and Health Systems
13 janv. 2025 10h00 HE
|
Baylor Genetics
Baylor Genetics announced its integration with Aura, the specialty diagnostics suite from leading electronic health record (EHR) company Epic.
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
09 janv. 2025 16h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced it signed an agreement with sports broadcaster Hannah Storm to promote the importance of knowing family cancer history.
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
08 janv. 2025 11h27 HE
|
Myriad Genetics, Inc.
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
08 janv. 2025 08h00 HE
|
Myriad Genetics, Inc.
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
07 janv. 2025 08h00 HE
|
Myriad Genetics, Inc.
The University of Texas MD Anderson Cancer Center and Myriad Genetics announced a five-year strategic alliance.
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
06 janv. 2025 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics released its Quality, Innovation, and Corporate Responsibility Report.
Genetic Testing Market Analysis with Forecasts Report 2025 with Executive and Consultant Guides, & Profiles of 140+ Companies
06 janv. 2025 07h58 HE
|
Research and Markets
Dublin, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The "Genetic Testing Markets. Global Market Analysis with Forecasts by Applications, Technologies, Products and Users with Executive and Consultant Guides"...